Abstract
The COVID-19 pandemic remains unrelenting as the autumn of 2020 approaches. Despite many clinical trials underway to find effective treatments for COVID-19, few studies have yielded positive results. Increasing evidence shows diffuse activation of the complement pathway in severe COVID-19 infections, from increased serum levels to widespread deposition in autopsy specimens.1–4 Initial case reports and case series using complement inhibitors in COVID-19 have shown promising results.5–8 The complement pathway, a key effector of the innate immune system, has emerged as a nidus of investigation in this pandemic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
